Charles River Laboratories International Inc. and CHDI Foundation, Inc. have announced an extension of their ongoing drug discovery partnership aimed at advancing therapeutic development for Huntington's disease. This extension marks the 20-year anniversary of their collaboration, which began in 2005. The renewed agreement will enhance flexibility and integration across Charles River's global scientific network, supporting CHDI's programs. The partnership has contributed to significant advancements, including novel drug targets, translational research models, and preclinical evaluations of therapeutic candidates. The collaboration has also resulted in 15 composition of matter patent applications, reflecting its impact on Huntington's disease research and potential treatment options.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。